Vi­a­tris leans in on brand drug port­fo­lio for fu­ture growth

Vi­a­tris, the bio­phar­ma formed by the merg­er of gener­ic gi­ants My­lan and Pfiz­er’s Up­john, is lean­ing in­to its brand­ed prod­ucts. Its growth strat­e­gy in­cludes dou­bling down on brand man­age­ment along with an an­tic­i­pat­ed $500 mil­lion-plus in new prod­uct launch sales this year, said pres­i­dent Ra­jiv Ma­lik dur­ing its Q1 earn­ings on Mon­day.

Brands ac­count­ed for two-thirds of its sales in the quar­ter at $2.4 bil­lion, led by Lip­i­tor ($418 mil­lion), Nor­vasc ($203 mil­lion), Lyri­ca ($144 mil­lion) and Vi­a­gra ($115 mil­lion), al­though all four brands record­ed de­clines year over year. Gener­ic sales notched $1.16 bil­lion in sales for the quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER